These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 19949390)

  • 1. Targeting RNA: an emerging hope for treating muscular dystrophy.
    Extance A
    Nat Rev Drug Discov; 2009 Dec; 8(12):917-8. PubMed ID: 19949390
    [No Abstract]   [Full Text] [Related]  

  • 2. Exploring the frontiers of therapeutic exon skipping for Duchenne muscular dystrophy by double targeting within one or multiple exons.
    Aartsma-Rus A; Kaman WE; Weij R; den Dunnen JT; van Ommen GJ; van Deutekom JC
    Mol Ther; 2006 Sep; 14(3):401-7. PubMed ID: 16753346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Molecular therapy for duchenne muscular dystrophy].
    Takeshima Y
    Nihon Rinsho; 2005 Dec; 63 Suppl 12():626-31. PubMed ID: 16416864
    [No Abstract]   [Full Text] [Related]  

  • 4. Antisense oligonucleotides in the treatment of Duchenne muscular dystrophy: Where are we now?
    Wilton SD; Fletcher S
    Neuromuscul Disord; 2005 Jun; 15(6):399-402. PubMed ID: 15907285
    [No Abstract]   [Full Text] [Related]  

  • 5. 128th ENMC International Workshop on 'Preclinical optimization and Phase I/II Clinical Trials Using Antisense Oligonucleotides in Duchenne Muscular Dystrophy' 22-24 October 2004, Naarden, The Netherlands.
    Muntoni F; Bushby K; van Ommen G
    Neuromuscul Disord; 2005 Jun; 15(6):450-7. PubMed ID: 15907292
    [No Abstract]   [Full Text] [Related]  

  • 6. [Exon skipping in Duchenne's muscular dystrophy].
    Nau JY
    Rev Med Suisse; 2008 Jan; 4(140):176. PubMed ID: 18309885
    [No Abstract]   [Full Text] [Related]  

  • 7. [Experimental therapy in Duchenne muscular dystrophy].
    van den Bergen JC; Straathof CS; Aartsma-Rus A; Ginjaar IB; Verschuuren JJ
    Ned Tijdschr Geneeskd; 2009 May; 153(18):870-5. PubMed ID: 19475867
    [No Abstract]   [Full Text] [Related]  

  • 8. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations.
    Aartsma-Rus A; Fokkema I; Verschuuren J; Ginjaar I; van Deutekom J; van Ommen GJ; den Dunnen JT
    Hum Mutat; 2009 Mar; 30(3):293-9. PubMed ID: 19156838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Technology insight: therapy for Duchenne muscular dystrophy-an opportunity for personalized medicine?
    Lim LE; Rando TA
    Nat Clin Pract Neurol; 2008 Mar; 4(3):149-58. PubMed ID: 18268530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 10th Oligonucleotide Therapy Approved: Golodirsen for Duchenne Muscular Dystrophy.
    Aartsma-Rus A; Corey DR
    Nucleic Acid Ther; 2020 Apr; 30(2):67-70. PubMed ID: 32043902
    [No Abstract]   [Full Text] [Related]  

  • 11. Targeting RNA to treat neuromuscular disease.
    Muntoni F; Wood MJ
    Nat Rev Drug Discov; 2011 Aug; 10(8):621-37. PubMed ID: 21804598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 149th ENMC International Workshop and 1st TREAT-NMD Workshop on: "planning phase i/ii clinical trials using systemically delivered antisense oligonucleotides in duchenne muscular dystrophy".
    Muntoni F; Bushby KD; van Ommen G
    Neuromuscul Disord; 2008 Mar; 18(3):268-75. PubMed ID: 18207401
    [No Abstract]   [Full Text] [Related]  

  • 13. [Treatment of Duchenne muscular dystrophy by induction of skipping of dystrophi exon].
    Matsuo M; Yagi M; Takeshima Y
    Rinsho Shinkeigaku; 2006 Nov; 46(11):936-8. PubMed ID: 17432225
    [No Abstract]   [Full Text] [Related]  

  • 14. Development of antisense-mediated exon skipping as a treatment for duchenne muscular dystrophy.
    Heemskerk H; de Winter CL; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
    Ann N Y Acad Sci; 2009 Sep; 1175():71-9. PubMed ID: 19796079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ASO Therapy: Hope for Genetic Neurological Diseases.
    Muth CC
    JAMA; 2018 Feb; 319(7):644-646. PubMed ID: 29383373
    [No Abstract]   [Full Text] [Related]  

  • 16. The development of antisense oligonucleotide therapies for Duchenne muscular dystrophy: report on a TREAT-NMD workshop hosted by the European Medicines Agency (EMA), on September 25th 2009.
    Muntoni F;
    Neuromuscul Disord; 2010 May; 20(5):355-62. PubMed ID: 20347306
    [No Abstract]   [Full Text] [Related]  

  • 17. Genetics. Hopping to a better protein.
    Pennisi E
    Science; 2008 Dec; 322(5907):1454-5. PubMed ID: 19056949
    [No Abstract]   [Full Text] [Related]  

  • 18. Nucleic acid therapeutics: a work in progress.
    Opalinska JB; Gewirtz AM
    Curr Opin Investig Drugs; 2002 Jun; 3(6):928-33. PubMed ID: 12137416
    [No Abstract]   [Full Text] [Related]  

  • 19. The therapeutic potential of antisense-mediated exon skipping.
    van Ommen GJ; van Deutekom J; Aartsma-Rus A
    Curr Opin Mol Ther; 2008 Apr; 10(2):140-9. PubMed ID: 18386226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisense Oligonucleotides for Duchenne Muscular Dystrophy: Why No Neurologist Should Skip This.
    Jacobson RD; Feldman EL
    JAMA Neurol; 2016 Mar; 73(3):259-60. PubMed ID: 26746046
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.